Dynamics of survival in patients with ovarian cancer III-IV degree
2017
The aim of the study was assessment of survival dynamics of ovarian cancer. The survey was conducted on the basis of OOD (c. Odessa) for 2010 - 2015 were examined 350 patients with ovarian adenocarcinoma of III-IV stage, which was carried with cytoreduction surgery. The average age of patients was 55,3 ± 3,9 years. The sample was dominated by patients with stage IIIC - on average there were 64.9% of the total sample. It is shown that the introduction of integrated circuits based pathogenesis of drug therapy with considering the platinum-resistance can significantly prolong the survival of patients with ovarian cancer. Pathogenetic therapy based on pharmacogenetic peculiarities can significantly improve treatment outcomes (up to 33,1 ± 1,4 months in patients likely to platinum resistance and 36,8 ± 1,9 months in platinum sensitive cases). If probable platynorezystentnosti advisable due to the standard first-line therapy drug use dyzrehulyatsiynyh adjustment disorders (donors of nitric oxide, detoxicant, antyurykemichni means). With predictable platinum sensitivity the standard first-line treatment can be supplemented with medications improving tolerance to, but the use of the medications for correction of disregulatory disorders is inappropriate.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI